[{"id":"04b5fff0-3325-4a83-9d7a-6930c6fb5088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05907759","created_at":"2023-06-18T18:08:20.498Z","updated_at":"2025-02-25T14:42:08.936Z","phase":"Phase 2","brief_title":"Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma","source_id_and_acronym":"NCT05907759","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/10/2024","start_date":" 07/10/2024","primary_txt":" Primary completion: 08/01/2034","primary_completion_date":" 08/01/2034","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2025-02-14"},{"id":"e91a001c-1388-4b9d-9fd5-c4bd92315a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579523","created_at":"2021-01-18T21:51:25.345Z","updated_at":"2025-02-25T15:18:52.701Z","phase":"Phase 1","brief_title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","source_id_and_acronym":"NCT04579523","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"0c9c74d6-485b-4485-94f9-eb7a56d84916","acronym":"","url":"https://clinicaltrials.gov/study/NCT06549634","created_at":"2025-02-25T16:48:12.139Z","updated_at":"2025-02-25T16:48:12.139Z","phase":"","brief_title":"Biomarkers of AKI in Patients Receiving Daratumumab","source_id_and_acronym":"NCT06549634","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" DKK3","pipe":"","alterations":" ","tags":["DKK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-05"},{"id":"3339f750-4360-456a-b1ee-c276f0735a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473730","created_at":"2021-01-18T17:07:06.521Z","updated_at":"2025-02-25T17:29:38.839Z","phase":"Phase 1","brief_title":"Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03473730","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-01-30"},{"id":"2dc1fa48-405c-43a2-8874-34fe5b578aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04824794","created_at":"2022-12-14T16:58:25.975Z","updated_at":"2024-07-02T16:34:59.269Z","phase":"Phase 1/2","brief_title":"GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT04824794","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"d08b3f2e-b940-4c34-82e7-531cd52cc0cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401020","created_at":"2023-02-21T20:01:15.546Z","updated_at":"2024-07-02T16:35:03.034Z","phase":"Phase 1","brief_title":"First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","source_id_and_acronym":"NCT04401020","lead_sponsor":"Sanofi","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SAR442257"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 03/02/2024","primary_completion_date":" 03/02/2024","study_txt":" Completion: 08/14/2024","study_completion_date":" 08/14/2024","last_update_posted":"2024-05-17"},{"id":"b2fc6887-a084-4aa0-93a1-942ca0ac28d0","acronym":"MUKnineb","url":"https://clinicaltrials.gov/study/NCT03188172","created_at":"2021-01-18T15:43:10.893Z","updated_at":"2025-02-25T14:26:26.313Z","phase":"Phase 2","brief_title":"MUK Nine b: OPTIMUM Treatment Protocol","source_id_and_acronym":"NCT03188172 - MUKnineb","lead_sponsor":"University of Leeds","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-14"},{"id":"94c8991a-5401-4521-bceb-f4667098ab6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03035357","created_at":"2021-01-18T14:56:23.113Z","updated_at":"2024-07-02T16:35:06.269Z","phase":"Phase 2","brief_title":"Neoadjuvant Listeria or Daratumumab in Prostate Cancer","source_id_and_acronym":"NCT03035357","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2024-05-03"},{"id":"1fffbecc-9d1d-4405-aa75-3725ff51616b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807048","created_at":"2023-04-10T14:03:23.661Z","updated_at":"2024-07-02T16:35:07.816Z","phase":"Phase 2","brief_title":"Daratumumab in STK11 Mutated NSCLC","source_id_and_acronym":"NCT05807048","lead_sponsor":"NYU Langone Health","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-24"},{"id":"dc5b63d1-d71c-461a-9555-93d27bcb4d1c","acronym":"PRO00041908","url":"https://clinicaltrials.gov/study/NCT05038644","created_at":"2021-09-09T13:53:03.633Z","updated_at":"2024-07-02T16:35:11.572Z","phase":"Phase 1","brief_title":"XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia","source_id_and_acronym":"NCT05038644 - PRO00041908","lead_sponsor":"Ehab L Atallah","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XmAb968"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-03"},{"id":"6b3f889b-f740-4f3b-8cf4-23be6228dabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684108","created_at":"2021-01-19T20:47:15.713Z","updated_at":"2024-07-02T16:35:12.449Z","phase":"Phase 1","brief_title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","source_id_and_acronym":"NCT04684108","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG301 IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-28"},{"id":"7a7e78ae-33bd-4583-a3bd-e69587f5d1ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556332","created_at":"2021-01-18T17:30:18.830Z","updated_at":"2024-07-02T16:35:14.241Z","phase":"Phase 2","brief_title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03556332","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-03-18"},{"id":"96e82999-ebea-468e-ae05-e9929f4ac0ba","acronym":"DARANIVOVAX","url":"https://clinicaltrials.gov/study/NCT06015724","created_at":"2023-08-29T16:10:12.521Z","updated_at":"2025-02-25T14:18:13.340Z","phase":"Phase 2","brief_title":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06015724 - DARANIVOVAX","lead_sponsor":"Georgetown University","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-05"},{"id":"236caabf-f765-48c1-9acf-9e39f56bd762","acronym":"","url":"https://clinicaltrials.gov/study/NCT04466475","created_at":"2021-01-18T21:27:59.454Z","updated_at":"2024-07-02T16:35:21.519Z","phase":"Phase 1","brief_title":"Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma","source_id_and_acronym":"NCT04466475","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/27/2024","start_date":" 01/27/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-01-31"},{"id":"0b154df6-4ebb-42ce-a9c2-2bdabd8ac5fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06115135","created_at":"2023-11-02T15:13:03.515Z","updated_at":"2024-07-02T16:35:22.451Z","phase":"Phase 2","brief_title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06115135","lead_sponsor":"Oncotherapeutics","biomarkers":" BCL2 • TNFA","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-24"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"},{"id":"13d940c3-64f2-4c13-a92c-5be14974fb4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499808","created_at":"2021-01-18T17:13:44.637Z","updated_at":"2024-07-02T16:35:24.603Z","phase":"Phase 2","brief_title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","source_id_and_acronym":"NCT03499808","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" NPPB","pipe":" | ","alterations":" Chr t(11;14) • Chr t(4;14) • Chr t(14;16)","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sarclisa (isatuximab-irfc)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-04"},{"id":"5fbd1607-3a0e-4647-9158-4e60480d4470","acronym":"ISABEL","url":"https://clinicaltrials.gov/study/NCT04965155","created_at":"2021-07-16T13:53:20.587Z","updated_at":"2024-07-02T16:35:25.810Z","phase":"Phase 2","brief_title":"A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)","source_id_and_acronym":"NCT04965155 - ISABEL","lead_sponsor":"EMN Research Italy","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • Sarclisa (isatuximab-irfc) • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2021","start_date":" 03/21/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-12-19"},{"id":"1f17b25f-68c6-4567-8949-45ac3df1083a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04157517","created_at":"2021-01-18T20:16:52.449Z","updated_at":"2024-07-02T16:35:26.289Z","phase":"Phase 1/2","brief_title":"A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04157517","lead_sponsor":"Takeda","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • modakafusp alfa (TAK-573)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 11/04/2023","primary_completion_date":" 11/04/2023","study_txt":" Completion: 11/04/2023","study_completion_date":" 11/04/2023","last_update_posted":"2023-12-14"},{"id":"fd9ebc09-6d35-46a3-abd9-f9c124160735","acronym":"EAE120","url":"https://clinicaltrials.gov/study/NCT05280275","created_at":"2022-03-15T18:52:55.764Z","updated_at":"2025-02-25T13:12:55.381Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible","source_id_and_acronym":"NCT05280275 - EAE120","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/15/2026","study_completion_date":" 03/15/2026","last_update_posted":"2023-12-01"},{"id":"43e62691-00c7-4f18-90a0-335ab0e5f78a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01084252","created_at":"2021-01-18T04:16:33.894Z","updated_at":"2024-07-02T16:35:34.498Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","source_id_and_acronym":"NCT01084252","lead_sponsor":"Sanofi","biomarkers":" IFNG • IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Sarclisa (isatuximab-irfc)"],"overall_status":"Completed","enrollment":" Enrollment 351","initiation":"Initiation: 06/10/2010","start_date":" 06/10/2010","primary_txt":" Primary completion: 12/21/2018","primary_completion_date":" 12/21/2018","study_txt":" Completion: 07/13/2023","study_completion_date":" 07/13/2023","last_update_posted":"2023-10-06"},{"id":"295b0561-593e-4af2-bcb7-0b0537450f29","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896737","created_at":"2021-01-18T19:11:30.460Z","updated_at":"2024-07-02T16:35:37.895Z","phase":"Phase 2","brief_title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","source_id_and_acronym":"NCT03896737","lead_sponsor":"European Myeloma Network","biomarkers":" IGH","pipe":" | ","alterations":" IGH translocation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 401","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-09-07"},{"id":"9553b380-cc34-4290-aa5f-0fb22fe4ee0f","acronym":"AMC-105","url":"https://clinicaltrials.gov/study/NCT04139304","created_at":"2021-01-29T07:19:53.416Z","updated_at":"2024-07-02T16:35:38.442Z","phase":"Phase 1","brief_title":"A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma","source_id_and_acronym":"NCT04139304 - AMC-105","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Darzalex (daratumumab) • vincristine • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-08-31"},{"id":"dc0e259c-54c3-443d-979e-3cda462cee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634435","created_at":"2021-01-19T20:37:11.137Z","updated_at":"2024-07-02T16:35:38.764Z","phase":"Phase 1","brief_title":"Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients","source_id_and_acronym":"NCT04634435","lead_sponsor":"Biohaven Pharmaceuticals, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e noraramtide (BHV-1100) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-08-29"}]